| Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics |
102 |
| Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE) |
62 |
| Guidelines of care for the management of primary cutaneous melanoma |
57 |
| Psoriasis: Which therapy for which patient Psoriasis comorbidities and preferred systemic agents |
57 |
| Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee |
55 |
| Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies |
55 |
| Cutaneous squamous cell carcinoma Incidence, risk factors, diagnosis, and staging |
55 |
| Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study |
50 |
| Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics |
48 |
| Psoriasis: Which therapy for which patient Focus on special populations and chronic infections |
48 |
| Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial |
47 |
| Guidelines of care for the management of basal cell carcinoma |
43 |
| Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne |
42 |
| Guidelines of care for the management of cutaneous squamous cell carcinoma |
42 |
| Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort |
40 |
| Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial |
40 |
| Results of the 2016 International Skin Imaging Collaboration International Symposium on Biomedical Imaging challenge: Comparison of the accuracy of computer algorithms to dermatologists for the diagnosis of melanoma from dermoscopic images |
39 |
| Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities |
39 |
| Disease characteristics, clinical evaluation, and new perspectives on pathogenesis |
39 |
| Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis |
38 |
| Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark |
38 |
| Basal cell carcinoma Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations |
37 |
| Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis |
35 |
| Review of environmental effects of oxybenzone and other sunscreen active ingredients |
34 |
| Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase multicenter, randomized, double-blind, etanercept-and placebo-controlled study (CIMPACT) |
32 |
| Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study |
32 |
| Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials |
31 |
| Dupilumab: A review of its use in the treatment of atopic dermatitis |
30 |
| Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2) |
30 |
| Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE a 12-week randomized, double-blinded, placebo-controlled phase 2b trial |
30 |
| North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part I: Diagnosis, evaluation, and the use of complementary and procedural management |
30 |
| Onychomycosis Clinical overview and diagnosis |
30 |
| Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland |
29 |
| Onychomycosis Treatment and prevention of recurrence |
27 |
| North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management |
26 |
| Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study |
25 |
| A phase randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis |
25 |
| Merkel cell carcinoma: An update and review |
24 |
| Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy |
24 |
| A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics |
23 |
| Serlopitant reduced pruritus in patients with prurigo nodularis in a phase randomized, placebo-controlled trial |
22 |
| Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial |
22 |
| Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features |
22 |
| Smoking, but not alcohol, is associated with risk of psoriasis in a Taiwanese population-based cohort study |
21 |
| An appraisal of new treatment approaches and overview of current therapies |
21 |
| Ethnic differences and comorbidities of 909 prurigo nodularis patients |
21 |
| Cutaneous malignant melanoma incidence and mortality trends in Canada: A comprehensive population-based study |
20 |
| Emerging therapies for atopic dermatitis: JAK inhibitors |
20 |
| Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management |
20 |
| Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis |
20 |
